SDMHF Stock Chart & Stats
$229.00
$1.00(0.52%)
At close: 4:00 PM EDT
$229.00
$1.00(0.52%)
Day’s Range― - ―
52-Week Range$176.98 - $264.40
Previous CloseN/A
Volume155.00
Average Volume (3M)N/A
Market Cap
$22.29B
Enterprise Value$19.88K
Total Cash (Recent Filing)$203.90M
Total Debt (Recent Filing)$2.40B
Price to Earnings (P/E)65.5
Beta0.81
Next Earnings
Oct 22, 2026EPS Estimate
1.37Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)3.02
Shares Outstanding97,330,410
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$270.34Price Target Upside18.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5.84
Revenue Forecast (FY)$3.66B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelRecurring consumables create repeat revenue tied to customers’ ongoing production rather than only new equipment placements. Installed systems can also increase future demand for compatible proprietary consumables, supporting customer retention and revenue visibility.
Revenue RecoveryThe strong revenue rebound indicates recovering customer demand and improved operating scale after a weaker period. Sustained growth would strengthen utilization of the company’s bioprocessing platform and provide a foundation for further margin recovery.
Improved LeverageLower leverage and a larger equity base make the balance sheet more resilient than in 2023. Improved financial flexibility can support investment in bioprocessing innovation and customer programs while reducing pressure from debt servicing.
Bears Say
Depressed ProfitabilityProfitability remains well below prior peak levels despite the revenue rebound. Lower gross and net margins indicate that recovery is currently volume-led, leaving earnings more exposed if pricing, product mix or operating efficiency do not normalize.
Weak Cash ConversionOperating cash flow is solid and free cash flow has improved, but conversion remains weak and less consistent than revenue. This can constrain internally funded investment, debt reduction and shareholder returns if working-capital or capital-spending needs remain elevated.
Biopharma Demand ExposureDemand depends on customers’ manufacturing volumes and investment cycles, including facility construction and clinical-to-commercial progression. Delays in biotech funding, capacity expansion or product development could reduce equipment placements and related consumables pull-through.
Sartorius Stedim Biotech News
SDMHF FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was $176.98 and its highest was $264.40 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is $22.29B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Oct 22, 2026 which is in 52 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Jul 23, 2026. The company reported $1.442 earnings per share for the quarter, missing the consensus estimate of $1.457 by -$0.015.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Annually dividend of $0.801 which represents an annual dividend yield of 0.35%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.37.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of $1.442 in its last earnings report, missing expectations of $1.457. Following the earnings report the stock price went down -3.413%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in SDMHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
SDMHF Stock 12 Month Forecast
Average Price Target
$270.34
▲(18.05% Upside)
Ownership Overview
― Insiders
3.01% Mutual Funds
<0.01% Other Institutional Investors
94.00% Public Companies and
Individual Investors